FDA restructures, renames office that reviews cancer therapies

The FDA office that reviews applications for cancer therapies has been renamed and reorganized.The Center for Drug Evaluation and Research’s Office of Oncologic Diseases — formerly known as the Office of Hematology and Oncology Products — now is structured under terms of a modernization plan approved last fall.Richard Pazdur, MD — who served as director of the Office of Hematology and Oncology Products since 2005 — will serve as acting director of the reorganized entity.“As the practice of oncology and the treatments for these life-threatening diseases haveRead More

Share on facebook
Share on twitter
Share on linkedin